In the quest for a novel therapeutic target for cisplatin resistance, we previously identified the ROS-neutralizing SOD1 to be overexpressed in cisplatin-resistant ovarian cancer cell lines using quantitative label-free comparative proteomics analysis [16]. This evidence concerns the gene SOD1 and ovarian cancer.